Posted by Gary Schwitzer in Health care journalism
Here’s what CNN could/should have included in between breaths of its breathless hype of “breaking news…breakthrough…exclusive” reporting – what science journalist Paul Raeburn says “could be the worst case of hyping cancer cures I’ve ever seen, and I’ve seen a lot.”
The moon shot metaphor brings to mind previous goals set for cancer, such as Richard Nixon’s 1971 war on cancer. Another example is former National Cancer Institute Director Andrew von Eschenbach’s goal of eliminating suffering and death from cancer by 2015. Some researchers say such attempts to reduce cancer to an engineering problem ignore the disease’s complexity and the unpredictability of science.
“The problem is not just one engineering task; it’s a hundred different scientific problems. We’re making steady progress, but to say we’re going to eliminate suffering and even prevent death is fraught with a lot of difficulty,” says Bruce Chabner of Massachusetts General Hospital in Boston. Chabner also points out that pushing back cancer is a job bigger than one institution. “It’s going to take all the talent around the world.”
Lung cancer researcher John Minna of UT Southwestern Medical Center in Dallas likes the idea of “uniting everybody as a team,” but he also wonders whether “this is the right of one institution.” Some researchers suggest the program is actually a public relations effort to raise funds at a time when federal grants are scarce.
The announcement follows a bumpy first year for DePinho at MD Anderson. Last spring, he and his wife, researcher Lynda Chin, came under scrutiny after the state-funded Cancer Prevention and Research Institute of Texas (CPRIT) awarded a $20 million incubator grant to MD Anderson and Rice University after a 3-week review. CPRIT’s chief scientific officer, Nobelist Alfred Gilman, resigned partly over the grant, which was withdrawn and will be resubmitted again for a more in-depth review. Questions have also been raised involving DePinho’s ties to companies.
Despite DePinho’s problems, MD Anderson has lured some big names in the past year, including genomics researcher Andy Futreal from the Wellcome Trust Sanger Institute in the United Kingdom. Another recruit is James Allison of the Memorial Sloan-Kettering Cancer Center in New York City, who had developed a widely heralded new immunotherapy drug for melanoma.
Another issue, less connected to the Moonshot announcement but certainly still relevant, is what the Houston Chronicle and Retraction Watch blog reported, “M.D. Anderson professor under fraud probe.”
But resignations, questions about conflicts of interest and fraud probes are not likely to be the kinds of angles and issues one pursues when there are “exclusive” reporting arrangements between a news organization and a medical center.
Addendum on October 23, 2012: For another related followup, see “Did Texas cancer research institute meddle with peer review?” on the Knight Science Journalism Tracker.